Hollencrest Capital Management’s Definium Therapeutics DFTX Stock Holding History

Hollencrest Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$140K	Sell	7,386 -130	-2%	-$2.21K	0.01%	364
2025 Q4	$101K	Hold	7,516	–	–	﹤0.01%	446
2025 Q3	$88.6K	Buy	7,516 +300	+4%	+$2.8K	﹤0.01%	459
2025 Q2	$46.8K	Hold	7,216	–	–	﹤0.01%	528
2025 Q1	$42.2K	Hold	7,216	–	–	﹤0.01%	550
2024 Q4	$50.2K	Buy	7,216 +7,150	+10,833%	+$49.2K	﹤0.01%	534
2024 Q3	$376	Hold	66	–	–	﹤0.01%	1053
2024 Q2	$476	Hold	66	–	–	﹤0.01%	1025
2024 Q1	$620	Hold	66	–	–	﹤0.01%	990
2023 Q4	$242	Hold	66	–	–	﹤0.01%	997
2023 Q3	$207	Hold	66	–	–	﹤0.01%	1028
2023 Q2	$236	Hold	66	–	–	﹤0.01%	1075
2023 Q1	$209	Hold	66	–	–	﹤0.01%	1093
2022 Q4	$145	Buy	+66	New	+$183	﹤0.01%	1101

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Hollencrest Capital Management's DFTX Position: Q1 2026 in Review

Hollencrest Capital Management reduced its Definium Therapeutics (DFTX) stake by 1.7% in Q1 2026, selling an estimated $2.21K and leaving 7,386 shares worth $140K. The position accounts for 0.01% of the portfolio, ranked #364.

Hollencrest Capital Management first reported a position in DFTX in Q4 2022 and has held it in 14 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

Hollencrest Capital Management held 7,386 shares of Definium Therapeutics worth $140K as of Q1 2026.
Hollencrest Capital Management sold 130 Definium Therapeutics shares in Q1 2026, an estimated $2.21K.
Definium Therapeutics made up 0.01% of Hollencrest Capital Management's portfolio in Q1 2026, its #364 holding.
Hollencrest Capital Management first reported a position in Definium Therapeutics in Q4 2022 and has held it in 14 quarters since.
247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Hollencrest Capital Management's 13F filing for Q1 2026, filed 7 May 2026.